Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

MK-2225 (ACE-1334)

Status:

Phase 1

Condition:

Systemic Sclerosis ILD

Intervention Type:

Subcutaneous (SC) Injection

Funder Type:

Industry

Drug Details

MK-2225 (ACE-1334) is designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2.

Study Purpose

This Phase 1b/2 study is designed to assess the safety, efficacy, PK, and PD of ACE-1334 plus SOC in participants with diffuse Systemic Sclerosis (SSc) with or without ILD (Phase 1b) and SSc-ILD (Phase 2).

Find a Clinical Trial